Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study
- PMID: 15136304
- DOI: 10.1001/archinte.164.9.963
Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study
Abstract
Background: There is limited information about risk factors for venous thromboembolism (VTE) in acutely ill hospitalized general medical patients.
Methods: An international, randomized, double-masked, placebo-controlled trial (MEDENOX) has previously been conducted in 1102 acutely ill, immobilized general medical patients and has shown the efficacy of using a low-molecular-weight heparin, enoxaparin sodium, in preventing thrombosis. We performed logistic regression analysis to evaluate the independent nature of different types of acute medical illness (heart failure, respiratory failure, infection, rheumatic disorder, and inflammatory bowel disease) and predefined factors (chronic heart and respiratory failure, age, previous VTE, and cancer) as risk factors for VTE.
Results: The primary univariate analysis showed that the presence of an acute infectious disease, age older than 75 years, cancer, and a history of VTE were statistically significantly associated with an increased VTE risk. Multiple logistic regression analysis indicated that these factors were independently associated with VTE.
Conclusions: Several independent risk factors for VTE were identified. These findings allow recognition of individuals at increased risk of VTE and will contribute to the formulation of an evidence-based risk assessment model for thromboprophylaxis in hospitalized general medical patients.
Comment in
-
Risk factors for venous thromboembolism.Arch Intern Med. 2004 Nov 22;164(21):2386. doi: 10.1001/archinte.164.21.2386-b. Arch Intern Med. 2004. PMID: 15557421 No abstract available.
Similar articles
-
Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada.Thromb Res. 2007;119(2):145-55. doi: 10.1016/j.thromres.2006.01.011. Epub 2006 Mar 3. Thromb Res. 2007. PMID: 16516275
-
Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients.Thromb Haemost. 2005 Oct;94(4):750-9. Thromb Haemost. 2005. PMID: 16270626 Review.
-
Venous thromboembolism in the medically ill patient: a call to action.Int J Clin Pract. 2005 May;59(5):555-61. doi: 10.1111/j.1368-5031.2005.00529.x. Int J Clin Pract. 2005. PMID: 15857352 Review.
-
Preventing venous thromboembolism in acute medical patients.QJM. 2004 Dec;97(12):797-801. doi: 10.1093/qjmed/hch128. QJM. 2004. PMID: 15569811
-
Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.Am J Manag Care. 2002 Dec;8(12):1082-8. Am J Manag Care. 2002. PMID: 12500884 Clinical Trial.
Cited by
-
Postoperative venous thromboembolism risk in patients with vulvar carcinoma: An analysis of the National surgical Quality Improvement Program (NSQIP) database.Gynecol Oncol Rep. 2024 May 12;54:101411. doi: 10.1016/j.gore.2024.101411. eCollection 2024 Aug. Gynecol Oncol Rep. 2024. PMID: 38803657 Free PMC article.
-
Risk factors for venous thromboembolism in patients with pneumonia in the pre-COVID-19 era: a meta-analysis and systematic review.J Thorac Dis. 2023 Dec 30;15(12):6697-6707. doi: 10.21037/jtd-23-926. Epub 2023 Dec 26. J Thorac Dis. 2023. PMID: 38249878 Free PMC article.
-
Computational identification and clinical validation of a novel risk signature based on coagulation-related lncRNAs for predicting prognosis, immunotherapy response, and chemosensitivity in colorectal cancer patients.Front Immunol. 2023 Oct 19;14:1279789. doi: 10.3389/fimmu.2023.1279789. eCollection 2023. Front Immunol. 2023. PMID: 37928532 Free PMC article.
-
Overuse and underuse of thromboprophylaxis in medical inpatients.Res Pract Thromb Haemost. 2023 Aug 23;7(6):102184. doi: 10.1016/j.rpth.2023.102184. eCollection 2023 Aug. Res Pract Thromb Haemost. 2023. PMID: 37745158 Free PMC article.
-
Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial.Liver Cancer. 2022 Jul 13;11(6):558-571. doi: 10.1159/000525671. eCollection 2022 Dec. Liver Cancer. 2022. PMID: 36589722 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical